Behavioral and Psychological Symptoms of Dementia and Antipsychotic Drug Use in the Elderly with Dementia in Korean Long-Term Care Facilities
Tóm tắt
Từ khóa
Tài liệu tham khảo
O’Donnell BF, Drachman DA, Barnes HJ, et al. Incontinence and troublesome behaviors predict institutionalization in dementia. J Geriatr Psychiatry Neurol. 1992;5:45–52.
Steele C, Rovner B, Chase GA, et al. Psychiatric symptoms and nursing home placement of patients with Alzheimer’s disease. Am J Psychiatry. 1990;147:1049–51.
De Vugt ME, Stevens F, Aalten P, et al. A prospective study of the effects of behavioral symptoms on the institutionalization of patients with dementia. Int Psychogeriatr. 2005;17:577–89.
Ryu SH, Ha JH, Park DH, et al. Persistence of neuropsychiatric symptoms over six months in mild cognitive impairment in community-dwelling Korean elderly. Int Psychogeriatr. 2011;23:214–20.
Tan LL, Wong HB, Allen H. The impact of neuropsychiatric symptoms of dementia on distress in family and professional caregivers in Singapore. Int Psychogeriatr. 2005;17:253–63.
Huang SS, Lee MC, Liao YC, et al. Caregiver burden associated with behavioral and psychological symptoms of dementia (BPSD) in Taiwanese elderly. Arch Gerontol Geriatr. 2012;55:55–9.
Hermann N. Recommendations for the management of behavioural and psychological symptoms of dementia. Can J Neuro Sci. 2001;28:96–107.
Lövheim H, Sandman PO, Kallin K, Karlsson S, Gustafson Y. Relationship between antipsychotic drug use and behavioral and psychological symptoms of dementia in old people with cognitive impairment living in geriatric care. Int Psychogeriatr. 2006;18:713–26.
Food and Drug Agency. Public Health Advisory: Deaths with antipsychotics in elderly patients with behavioural disturbances. Silver Spring (MD): US Food and Drug Administration. 2005. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm150688.htm . Accessed 22 Jun 2015.
European Medicines Agency. CHMP Assessment Report on Conventional Antipsychotics. EMA. 2008. http://www.ema.europa.eu/docs/en_GB/document_library/Other/2012/05/WC500127477.pdf . Accessed 22 Jun 2015.
Liperoti R, Mor V, Lapane KL, et al. The use of atypical antipsychotics in nursing homes. J Clin Psychiatry. 2003;64:1106–12.
Briesacher BA, Limcangco MR, Simoni-Wastila L, et al. The quality of antipsychotic drug prescribing in nursing homes. Arch Intern Med. 2005;165:1280–5.
Bronskill SE, Anderson GM, Sykora K, et al. Neuroleptic drug therapy in older adults newly admitted to nursing homes: incidence, dose and specialist contact. J Am Geriatr Soc. 2004;52:749–55.
Rochon PA, Stukel TA, Bronskill SE, et al. Variation in nursing home antipsychotic prescription rates. Arch Intern Med. 2007;167:676–83.
Chen Y, Briesacher B, Field T, et al. Unexplained variation across US nursing homes in antipsychotic prescribing rates. Arch Intern Med. 2010;170:89–95.
Azermai M. Dealing with behavioral and psychological symptoms of dementia: a general overview. Psychol Res Behav Manag. 2015;8:181–5.
Agency for Healthcare Research and Quality. Off-label use of atypical antipsychotics: an update. No 43. Rockville, MD, USA: comparative effectiveness reviews; 2011. http://www.ncbi.nlm.nih.gov/books/NBK66081/ . Accessed 7 Sep 2015.
OECD. Policy brief. Ensuring quality long-term care for older people. Paris: OECD; 2005. http://www.oecd.org/els/health-systems/Ensuring-quality-long-term-care-for-older-people.pdf . Accessed 22 Jun 2015.
Wiener JM, Tilly J, Howe A, et al. Quality assurance for long-term care: the experiences of England, Australia, Germany and Japan. Washington, DC: AARP; 2007.
Ribbe MW, Ljunggren G, Steel K, et al. Nursing homes in 10 nations: a comparison between countries and settings. Age Ageing. 1997;26(Suppl 2):3–12.
Jung Sun-Young, Kwon In Soon, Cho BeLong, Yoon Jong Lull, Rho Yong Gyun, Lee Eunju, et al. Reliability and Validity of Korean brief comprehensive geriatric assessment questionnaire. J Korean Geriatr So. 2006;10(2):67–76.
Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci. 2000;12(2):233–9.
WHO Collaborating Centre for drug statistics methodology: ATC index with DDDs. [ http://www.whocc.no ]. Accessed 22 Jun 2015.
Alanen HM, Finne-Soveri H, Noro A, Leinonen E. Use of antipsychotics among nonagenarian residents in long-term institutional care in Finland. Age Ageing. 2006;35(5):508–13.
Hosia-Randell H, Pitkälä K. Use of psychotropic drugs in elderly nursing home residents with and without dementia in Helsinki, Finland. Drugs Aging. 2005;22(9):793–800.
Oborne CA, Hooper R, Li KC, et al. An indicator of appropriate neuroleptic prescribing in nursing homes. Age Ageing. 2002;31:435–9.
Nishtala PS, McLachlan AJ, Bell JS, Chen TF. Determinants of antipsychotic medication use among older people living in aged care homes in Australia. Int J Geriatr Psychiatry. 2010;25(5):449–57.
Macdonald AJ, Carpenter GI, Box O, Roberts A, Sahu S. Dementia and use of psychotropic medication in non-“Elderly Mentally Infirm” nursing homes in South East England. Age Ageing. 2002;31(1):58–64.
Nobili A, Pasina L, Trevisan S, Riva E, Lucca U, Tettamanti M, et al. Use and misuse of antipsychotic drugs in patients with dementia in Alzheimer special care units. Int Clin Psychopharmacol. 2009;24(2):97–104.
Alexopoulos GS, Streim J, Carpenter D, Docherty JP. Using antipsychotic agents in older patients. J Clin Psychiatry. 2004;65(Suppl 2):5–99 (discussion 100–102; quiz 103–4).
Ballard C, Creese B, Corbett A, Aarsland D. Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality. Expert Opin Drug Saf. 2011;10:35–43.